Pursuit of precision oncology in the treatment of metastatic hormone receptor–positive breast cancer: Making strides or barely moving?
I
Ilana Schlam
(Dana‐Farber Cancer Institute Harvard Medical School Boston Massachusetts USA)
A
Ajay Dhakal
(Wilmot Cancer Institute University of Rochester Medical Center Rochester New York USA)
Article Details
Volume / Issue
Vol. 76, Issue 1
Published
January 01, 2026
ISSN
0007-9235
Publisher
Wiley
Authors (2)
I
Ilana Schlam
Dana‐Farber Cancer Institute Harvard Medical School Boston Massachusetts USA
A
Ajay Dhakal
Wilmot Cancer Institute University of Rochester Medical Center Rochester New York USA
Related Articles from this Journal
Systemic amyloid light‐chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates
Xia Wu, Heather Landau et al.
May 2026
10.3322/caac.70092
Screening for colorectal cancer
May 2026
10.3322/caac.70087
Correction to “Integrating multimodal management and molecular profiling in a patient with BRAF V600E–positive melanoma and brain metastases”
May 2026
10.3322/caac.70093
Blood tests for colorectal cancer—Hype ahead of evidence?
Gloria D. Coronado, David A. Lieberman
May 2026
10.3322/caac.70088
Medullary thyroid carcinoma and <i>RET</i> molecular testing: A virtual tumor board on clinical decision‐making
Lucas Kallas‐Silva, Victor Alexandre dos Santos Valsecchi et al.
May 2026
10.3322/caac.70086